PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.
about
In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumoursNimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.NK Cell Exhaustion.Immune checkpoints on innate lymphoid cells.Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection.Control of NK Cell Activation by Immune Checkpoint Molecules.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.Broad Impairment of Natural Killer Cells from Operationally Tolerant Kidney Transplanted Patients.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells.Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.Decreased Siglec-9 Expression on Natural Killer Cell Subset Associated With Persistent HBV Replication.Next generation immune-checkpoints for cancer therapy.Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer CellsEndogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cellsAvelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
P2860
Q33605673-1E3314FC-0043-42C3-87BF-394BF073512CQ33786422-ADE27535-1EC6-43B3-8954-75DD0529553AQ33809528-8FCEB207-086C-4206-A4B0-61AA3773AFEDQ33839204-5B109259-5F7C-4418-8418-7D8D3DE20BB2Q37739485-7F3F02FE-BAEF-4D19-A478-2C67378A7ADBQ39431541-9B4DCEFC-4D13-47B0-9713-C3AAF51E8A28Q40208844-8B808A3D-47AA-43CA-9A70-F6D41474C09CQ41919772-BAD6633D-0445-42B6-AFAA-EEA13A8E57F0Q41923721-03041B32-D2D6-4A99-8E63-39561C940C70Q47128718-86116FF6-C961-4A63-BE11-21C225627CA5Q47156322-664C1194-85A5-48FA-AEE0-CB6E4569BAF4Q47165141-14D202BB-2101-406F-B379-563F88402FCCQ47343260-0640B0BF-40EC-4991-A3A2-283251622DFFQ49830211-4BB038D7-4114-446F-AD90-3863811C3FA6Q49884881-4DAB5B81-08F7-4526-8ABD-1B3A608C6A83Q53068032-5F695D96-D038-4F07-AA75-DDC7D7909C3DQ55184907-9C37125B-05ED-4F38-A00D-A05161616D7EQ55259976-761E591A-3A96-4C56-B406-BBD15F18F90FQ55383705-EBF64AB6-2D45-4D5B-9385-BC9A03E1F5B8Q56889003-68AFB4C8-A47A-474C-BE01-D7DF6DFEEFDBQ57038956-22A78952-0C32-427A-BD0C-732E4A763C18Q57191726-8E737330-0574-4266-AA40-2BC144F3C889
P2860
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@en
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@nl
type
label
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@en
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@nl
prefLabel
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@en
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
PD-1 mediates functional exhau ...... patients with Kaposi sarcoma.
@en
P2093
Asma Beldi-Ferchiou
Céleste Lebbé
Damien Sène
Daniel Olive
David Zucman
Frank Levasseur
Frédéric Vély
Marion Lambert
Stéphanie Dupuy
P2860
P304
72961-72977
P356
10.18632/ONCOTARGET.12150
P407
P577
2016-09-20T00:00:00Z